| 000 | 01741 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250518065230.0 | ||
| 264 | 0 | _c20210608 | |
| 008 | 202106s 0 0 eng d | ||
| 022 | _a2405-4720 | ||
| 024 | 7 |
_a10.1016/j.cels.2019.10.002 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBolan, Patrick O | |
| 245 | 0 | 0 |
_aGenotype-Fitness Maps of EGFR-Mutant Lung Adenocarcinoma Chart the Evolutionary Landscape of Resistance for Combination Therapy Optimization. _h[electronic resource] |
| 260 |
_bCell systems _c01 2020 |
||
| 300 |
_a52-65.e7 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAcrylamides _xadministration & dosage |
| 650 | 0 | 4 |
_aAdenocarcinoma of Lung _xdrug therapy |
| 650 | 0 | 4 |
_aAniline Compounds _xadministration & dosage |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xpharmacology |
| 650 | 0 | 4 |
_aBenzimidazoles _xadministration & dosage |
| 650 | 0 | 4 |
_aDrug Resistance, Neoplasm _xgenetics |
| 650 | 0 | 4 |
_aErbB Receptors _xgenetics |
| 650 | 0 | 4 |
_aErlotinib Hydrochloride _xadministration & dosage |
| 650 | 0 | 4 | _aGenetic Fitness |
| 650 | 0 | 4 | _aGenotype |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLung Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aMAP Kinase Signaling System |
| 650 | 0 | 4 | _aMutation |
| 700 | 1 | _aZviran, Asaf | |
| 700 | 1 | _aBrenan, Lisa | |
| 700 | 1 | _aSchiffman, Joshua S | |
| 700 | 1 | _aDusaj, Neville | |
| 700 | 1 | _aGoodale, Amy | |
| 700 | 1 | _aPiccioni, Federica | |
| 700 | 1 | _aJohannessen, Cory M | |
| 700 | 1 | _aLandau, Dan A | |
| 773 | 0 |
_tCell systems _gvol. 10 _gno. 1 _gp. 52-65.e7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.cels.2019.10.002 _zAvailable from publisher's website |
| 999 |
_c30255752 _d30255752 |
||